Paul Spearman

List of Publications by Year
in descending order

99 papers	4,051 citations	87888 38 h-index	133252 59 g-index
104 all docs	104 docs citations	104 times ranked	4949 citing authors

#	Article	IF	Citations
1	Advances in HIV-1 Assembly. Viruses, 2022, 14, 478.	3.3	14
2	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. Clinical Infectious Diseases, 2021, 73, 336-340.	5.8	70
3	HIV Impairs Alveolar Macrophage Function via MicroRNA-144-Induced Suppression of Nrf2. American Journal of the Medical Sciences, 2021, 361, 90-97.	1.1	10
4	Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. Frontiers in Immunology, 2021, 12, 623996.	4.8	10
5	Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. Pediatric Infectious Disease Journal, 2021, 40, e234-e235.	2.0	2
6	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	6.0	7
7	Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution. Mucosal Immunology, 2021, 14, 1224-1234.	6.0	16
8	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2.5	4
9	Diagnostic testing for SARS-CoV-2/COVID19. Current Opinion in Pediatrics, 2021, 33, 122-128.	2.0	18
10	Pediatric Infectious Disease Specialists: An Answer to Social Media Misinformation on Coronavirus Disease 2019. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 703-705.	1.3	0
11	Comparative analysis of human microglial models for studies of HIV replication and pathogenesis. Retrovirology, 2020, 17, 35.	2.0	38
12	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. Journal of Virology, 2020, 94, .	3.4	17
13	HIV-1 Broadly Neutralizing Antibodies Take the Road Less Traveled, and That Makes All the Difference. Cell Host and Microbe, 2020, 27, 487-488.	11.0	1
14	Pediatric Infectious Diseases Meets the Future. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 9-12.	1.3	3
15	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. Journal of Infectious Diseases, 2019, 219, 1755-1765.	4.0	7
16	The future of careers in pediatric infectious diseases. Current Opinion in Pediatrics, 2019, 31, 144-147.	2.0	2
17	Challenges and solutions for instituting an efficient maintenance program for laboratory equipment in Central Asian, and developing world, countries. BMC Public Health, 2019, 19, 476.	2.9	3
18	The ability of SAMHD1 to block HIV-1 but not SIV requires expression of MxB. Virology, 2019, 531, 260-268.	2.4	14

#	Article	IF	Citations
19	Viral interactions with host cell Rab GTPases. Small GTPases, 2018, 9, 192-201.	1.6	61
20	HIV-1 Envelope Glycoprotein Trafficking through the Endosomal Recycling Compartment Is Required for Particle Incorporation. Journal of Virology, 2018, 92, .	3.4	42
21	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS ONE, 2018, 13, e0206837.	2.5	24
22	Targeted Elimination of Tumorigenic Human Pluripotent Stem Cells Using Suicide-Inducing Virus-like Particles. ACS Chemical Biology, 2018, 13, 2329-2338.	3.4	15
23	A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay. Journal of Immunological Methods, 2018, 460, 10-16.	1.4	8
24	HIV-related proteins prolong macrophage survival through induction of Triggering receptor expressed on myeloid cells-1. Scientific Reports, 2017, 7, 42028.	3.3	47
25	Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. Journal of Experimental Medicine, 2017, 214, 2139-2152.	8.5	106
26	HIV-1 decreases Nrf2/ARE activity and phagocytic function in alveolar macrophages. Journal of Leukocyte Biology, 2017, 102, 517-525.	3.3	38
27	Siglec-1 initiates formation of the virus-containing compartment and enhances macrophage-to-T cell transmission of HIV-1. PLoS Pathogens, 2017, 13, e1006181.	4.7	79
28	Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein. PLoS ONE, 2016, 11, e0158861.	2.5	8
29	EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression. PLoS Pathogens, 2016, 12, e1005622.	4.7	59
30	A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation. Vaccine, 2016, 34, 5571-5578.	3.8	10
31	Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. Journal of Virology, 2016, 90, 8842-8854.	3.4	34
32	A Putative Cyclin-binding Motif in Human SAMHD1 Contributes to Protein Phosphorylation, Localization, and Stability. Journal of Biological Chemistry, 2016, 291, 26332-26342.	3.4	21
33	A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nature Communications, 2016, 7, 12838.	12.8	55
34	Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Molecular Immunology, 2016, 70, 94-103.	2.2	12
35	Three-Dimensional Structural Characterization of HIV-1 Tethered to Human Cells. Journal of Virology, 2016, 90, 1507-1521.	3.4	27
36	Placental Hofbauer cells assemble and sequester HIVâ€1 in tetraspaninâ€positive compartments that are accessible to broadly neutralizing antibodies. Journal of the International AIDS Society, 2015, 18, 19385.	3.0	21

#	Article	IF	Citations
37	HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans. EBioMedicine, 2015, 2, 1464-1477.	6.1	60
38	A tyrosine-based motif in the HIV-1 envelope glycoprotein tail mediates cell-typeâ€“ and Rab11-FIP1Câ€“dependent incorporation into virions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7575-7580.	7.1	50
39	P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. Journal of Virology, 2015, 89, 9368-9382.	3.4	23
40	Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration. Aids, 2015, 29, 390-392.	2.2	5
41	HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors. Current Topics in Medicinal Chemistry, 2015, 16, 1154-1166.	2.1	23
42	Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infectious Diseases, 2014, 1, ofu102.	0.9	11
43	ROCK1 and LIM Kinase Modulate Retrovirus Particle Release and Cell-Cell Transmission Events. Journal of Virology, 2014, 88, 6906-6921.	3.4	46
44	Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1420.	7.4	45
45	Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1409.	7.4	126
46	Direct evidence for intracellular anterograde co-transport of M-PMV Gag and Env on microtubules. Virology, 2014, 449, 109-119.	2.4	16
47	Microscale Generation of Cardiospheres Promotes Robust Enrichment of Cardiomyocytes Derived from Human Pluripotent Stem Cells. Stem Cell Reports, 2014, 3, 260-268.	4.8	73
48	Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine, 2014, 32, 6284-6293.	3.8	10
49	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	7.1	197
50	Methicillin-resistant Staphylococcus aureus Empyema Necessitatis in a Breast-fed Neonate. Pediatric Infectious Disease Journal, 2014, 33, 668-669.	2.0	6
51	An siRNA Screen of Membrane Trafficking Genes Highlights Pathways Common to HIV-1 and M-PMV Virus Assembly and Release. PLoS ONE, 2014, 9, e106151.	2.5	15
52	Rab11-FIP1C and Rab14 Direct Plasma Membrane Sorting and Particle Incorporation of the HIV-1 Envelope Glycoprotein Complex. PLoS Pathogens, 2013, 9, e1003278.	4.7	91
53	A Mason-Pfizer Monkey Virus Gag-GFP Fusion Vector Allows Visualization of Capsid Transport in Live Cells and Demonstrates a Role for Microtubules. PLoS ONE, 2013, 8, e83863.	2.5	9
54	Defective HIV-1 Particle Assembly in AP-3-Deficient Cells Derived from Patients with Hermansky-Pudlak Syndrome Type 2. Journal of Virology, 2012, 86, 11242-11253.	3.4	15

#	Article	IF	Citations
55	The Tetherin/BST-2 Coiled-Coil Ectodomain Mediates Plasma Membrane Microdomain Localization and Restriction of Particle Release. Journal of Virology, 2012, 86, 2259-2272.	3.4	34
56	Restriction of Retroviral Replication by Tetherin/BST-2. Molecular Biology International, 2012, 2012, 1-9.	1.7	9
57	Tetherin/BST-2 Is Essential for the Formation of the Intracellular Virus-Containing Compartment in HIV-Infected Macrophages. Cell Host and Microbe, 2012, 12, 360-372.	11.0	70
58	The HIV-1 matrix protein does not interact directly with the protein interactive domain of AP-3Î´. Virus Research, 2012, 169, 411-414.	2.2	6
59	Different Pattern of Immunoglobulin Gene Usage by HIV-1 Compared to Non-HIV-1 Antibodies Derived from the Same Infected Subject. PLoS ONE, 2012, 7, e39534.	2.5	30
60	The Intracellular Virus-Containing Compartments in Primary Human Macrophages Are Largely Inaccessible to Antibodies and Small Molecules. PLoS ONE, 2012, 7, e35297.	2.5	42
61	Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology, 2011, 8, 26.	2.0	37
62	Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators. Journal of Bone and Mineral Research, 2011, 26, 1913-1925.	2.8	4
63	Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant. Journal of Infectious Diseases, 2011, 203, 666-673.	4.0	56
64	Identification of a Single Amino Acid Required for APOBEC3 Antiretroviral Cytidine Deaminase Activity. Journal of Virology, 2011, 85, 5691-5695.	3.4	21
65	Filamin A Protein Interacts with Human Immunodeficiency Virus Type 1 Gag Protein and Contributes to Productive Particle Assembly. Journal of Biological Chemistry, 2011, 286, 28498-28510.	3.4	42
66	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases, 2011, 203, 1165-1173.	4.0	71
67	Immunoelectron Microscopic Evidence for Tetherin/BST2 as the Physical Bridge between HIV-1 Virions and the Plasma Membrane. PLoS Pathogens, 2010, 6, e1000749.	4.7	130
68	An Imperfect Rule for the Particle Roost. Cell Host and Microbe, 2010, 7, 261-263.	11.0	2
69	CAML Does Not Modulate Tetherin-Mediated Restriction of HIV-1 Particle Release. PLoS ONE, 2010, 5, e9005.	2.5	4
70	Tetherin Is as Tetherin Does. Cell, 2009, 139, 456-457.	28.9	9
71	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine, 2009, 27, 243-249.	3.8	55
72	NEISSERIA SICCA/SUBFLAVA BACTEREMIA PRESENTING AS CUTANEOUS NODULES IN AN IMMUNOCOMPROMISED HOST. Pediatric Infectious Disease Journal, 2009, 28, 661-663.	2.0	9

#	Article	IF	Citations
73	Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nature Medicine, 2008, 14, 641-647.	30.7	36
74	The Impact of Cesarean Delivery on Transmission of Infectious Agents to the Neonate. Clinics in Perinatology, 2008, 35, 407-420.	2.1	11
75	Direct Comparison of Antigen Production and Induction of Apoptosis by Canarypox Virus- and Modified Vaccinia Virus Ankara-Human Immunodeficiency Virus Vaccine Vectors. Journal of Virology, 2007, 81, 7022-7033.	3.4	23
76	Myristoylation Is Required for Human Immunodeficiency Virus Type 1 Gag-Gag Multimerization in Mammalian Cells. Journal of Virology, 2007, 81, 12899-12910.	3.4	78
77	APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker. Journal of Virology, 2007, 81, 5000-5013.	3.4	99
78	Cellular cofactors involved in HIV assembly and budding. Current Opinion in HIV and AIDS, 2006, 1, 200-207.	3.8	6
79	The Pericentriolar Recycling Endosome Plays a Key Role in Vpuâ€mediated Enhancement of HIVâ€1 Particle Release. Traffic, 2006, 7, 298-307.	2.7	89
80	Current Progress in the Development of HIV Vaccines. Current Pharmaceutical Design, 2006, 12, 1147-1167.	1.9	44
81	Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization. Journal of Virology, 2005, 79, 14804-14814.	3.4	51
82	Pseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses. Journal of Virology, 2005, 79, 5537-5547.	3.4	18
83	AP-3 Directs the Intracellular Trafficking of HIV-1 Gag and Plays a Key Role in Particle Assembly. Cell, 2005, 120, 663-674.	28.9	210
84	A Novel Fluorescence Resonance Energy Transfer Assay Demonstrates that the Human Immunodeficiency Virus Type 1 Pr55 Gag I Domain Mediates Gag-Gag Interactions. Journal of Virology, 2004, 78, 1230-1242.	3.4	81
85	HIV-1 Egress is Gated Through Late Endosomal Membranes. Traffic, 2003, 4, 902-910.	2.7	159
86	Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15154-15159.	7.1	153
87	Independent Segregation of Human Immunodeficiency Virus Type 1 Gag Protein Complexes and Lipid Rafts. Journal of Virology, 2003, 77, 1916-1926.	3.4	78
88	HIV Vaccine Development: Lessons from the Past and Promise for the Future. Current HIV Research, 2003, 1, 101-120.	0.5	53
89	Comparison of Roche MONITOR and Organon Teknika NucliSens Assays To Quantify Human Immunodeficiency Virus Type 1 RNA in Cerebrospinal Fluid. Journal of Clinical Microbiology, 2001, 39, 1612-1614.	3.9	5
90	Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clinical Pharmacology and Therapeutics, 2000, 68, 367-374.	4.7	41

#	Article	IF	Citations
91	Mapping and Characterization of the N-Terminal I Domain of Human Immunodeficiency Virus Type 1 Pr55Gag. Journal of Virology, 2000, 74, 7238-7249.	3.4	104
92	Evidence of a Source of HIV Type 1 within the Central Nervous System by Ultraintensive Sampling of Cerebrospinal Fluid and Plasma. AIDS Research and Human Retroviruses, 2000, 16, 1491-1502.	1.1	46
93	Comparison of Human Immunodeficiency Virus Type 1 RNA Sequence Heterogeneity in Cerebrospinal Fluid and Plasma. Journal of Clinical Microbiology, 2000, 38, 4637-4639.	3.9	31
94	Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). Journal of Medical Primatology, 1999, 28, 97-104.	0.6	18
95	Human Immunodeficiency Virus Replication in a Primary Effusion Lymphoma Cell Line Stimulates Lytic-Phase Replication of Kaposiâ€™s Sarcoma-Associated Herpesvirus. Journal of Virology, 1999, 73, 10329-10338.	3.4	78
96	ACUTE ASEPTIC MENINGITIS SECONDARY TO INTRAVENOUS IMMUNOGLOBULIN IN A PATIENT WITH KAWASAKI SYNDROME. Pediatric Infectious Disease Journal, 1998, 17, 1054-1056.	2.0	15
97	The I Domain Is Required for Efficient Plasma Membrane Binding of Human Immunodeficiency Virus Type 1 Pr55 ^{Gag}. Journal of Virology, 1998, 72, 2723-2732.	3.4	133
98	Dracunculiasis: Report of an Imported Case in the United States. Clinical Infectious Diseases, 1997, 25, 749-750.	5.8	14
99	Sternoclavicular joint septic arthritis with small-colony variant Staphylococcus aureus. Diagnostic Microbiology and Infectious Disease, 1996, 26, 13-15.	1.8	21